Every 10-Q that Aclarion, Inc. (ACON) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ACON and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACON filings page.
Aclarion, Inc., an early-stage healthcare technology company, generated modest revenue but continued sizable losses in the quarter ended June 30, 2026. Q2 revenue was $25,208 (first-half $46,348), while net losses were $2.7 million for the quarter and $5.6 million year‑to‑date.
Operating expenses rose sharply as the company invested in commercialization and product development. First-half operating expenses reached $5.9 million, driven by higher sales and marketing spending around the NOCISCAN report and CLARITY Trial, increased R&D, and greater legal, investor relations, and Delaware franchise tax costs.
Despite negative operating cash flow of $5.3 million in the first half, Aclarion strengthened its balance sheet via a January 2026 registered direct offering of common stock and pre-funded warrants, raising about $10.4 million. Cash, cash equivalents and restricted cash totaled $16.3 million at June 30, 2026, and management believes this will fund operations for at least twelve months, though additional capital may be needed to fully execute its strategy. Common shares outstanding increased to 2,462,250 at June 30, 2026, reflecting equity financings and warrant exercises.
Aclarion, Inc. reported a larger net loss for the quarter ended March 31, 2026, while significantly strengthening its cash position through new equity financing. Revenue rose modestly to $21,140 from $18,991, driven mainly by more Nociscan reports sold in the U.K.
Operating expenses nearly doubled to $2.99 million, reflecting higher sales and marketing spending around the CLARITY Trial, greater research and development, and increased general and administrative costs such as investor relations and Delaware franchise taxes. Net loss widened to $2.85 million from $2.04 million, or $(1.34) per share.
Cash, cash equivalents and restricted cash increased to $19.03 million, supported by a January 2026 registered direct offering of common stock and pre-funded warrants that generated roughly $10.4 million in gross proceeds. The company expects its current cash to fund operations into the second half of 2027. Subsequent to quarter-end, the board approved a $2.5 million share repurchase program and adopted a stockholder rights agreement intended to discourage hostile accumulations of its stock.
Aclarion, Inc. (ACON) reported Q3 2025 results. Revenue was $18,942, up modestly from $14,407 a year ago, with gross profit of $4,386 after a loss in the prior year period. Operating expenses rose to $1.84 million, leading to a net loss of $1.71 million versus $1.37 million a year earlier. For the first nine months, revenue reached $57,251 and net loss was $5.34 million.
The balance sheet strengthened following capital raises: cash and cash equivalents were $11.34 million versus $0.45 million at year‑end 2024, total assets were $13.20 million, liabilities were $0.70 million, and stockholders’ equity improved to $12.50 million. The company disclosed it raised an additional $2.5 million in October 2025 and believes its cash will fund operations through the first quarter of 2027. During 2025, Aclarion effected 1:335 and 1:27 reverse stock splits. Shares outstanding were 582,371 as of September 30, 2025; as context, 671,371 shares were outstanding as of November 10, 2025.